¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
Los agonistas del receptor del péptido similar al glucagón (AR-GLP1) y los inhibidores del cotransportador sodio glucosa tipo 2 (iSGLT-2) comparten una serie de acciones metabólicas, cardiovasculares y renales que los convierten en un dúo ideal para la terapia combinada. Utilizados en conjunto, cor...
Saved in:
Main Author: | Claudia Folino |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Sello Editorial Lugones
2024-10-01
|
Series: | Revista de la Sociedad Argentina de Diabetes |
Subjects: | |
Online Access: | https://www.revistasad.com/index.php/diabetes/article/view/992 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EVALUAREA EFICACITĂȚII TERAPIEI CU INHIBITORI SGLT2 LA PACIENȚII CU INSUFICIENȚĂ CARDIACĂ CU FRACȚIE DE EJECȚIE PĂSTRATĂ
by: Tatiana Cotonet, et al.
Published: (2025-03-01) -
The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older Persons with Diabetes
by: Alan Sinclair, et al.
Published: (2025-06-01) -
A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01) -
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01) -
Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice
by: Gašper Tonin, et al.
Published: (2025-07-01)